Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase
US11135206B2 · kind B2 · utility
0Cited by
2References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 26, 2016 |
| Grant date | Oct 5, 2021 |
| Priority date | — |
| Expiry date | May 26, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/03
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel pyrazolo[4,3-c]quinoline derivatives exhibiting specifically inhibition activity to microbiota β-glucuronidase, whereby providing potent activities to prevent chemotherapy-induced diarrhea (CID) of cancers. Therefore, the compounds of the present invention can be used as (1) chemotherapy-adjuvant to prevent chemotherapy-induced diarrhea (CID) and enhance chemotherapeutic efficiency of cancers; (2) health-food supplement to prevent the carcinogens induced colon carcinoma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.